• Home
  • About
    • Contact
    • Client Survey
  • Services
    • Health Care Reform Navigators
    • Strategic Benefits Planning
    • Employee Benefits >
      • Group Private Exchange
      • Group Medical Plans >
        • Fully-Insured Health Plans
        • Self-Funded Plans
        • Consumer-Driven Plans
        • Cafeteria Plans
        • SHOP Plans
        • RKA Benefits Blend
      • Group Life Insurance
      • Group Disability
      • Group Dental Plans
      • Group Vision Plans
      • Group Voluntary Benefits >
        • Value-Added Services
      • RKA Benefits Blend
    • PEOs - HR Outsourcing
    • Pricing
  • Get Quote
  • Benefits Edge
  • "Bill Please!" Forum
  • Employee Solution
    • Calculators
Rylan Klaseen & Associates
909-243-4886

Benefits Edge

From our team to yours.

Contact Rylan
Rylan Klaseen & Associates

Expensive Specialty Drugs and Their Consequences

6/16/2014

 
"...whenever the high price of pharmaceuticals is in the news, drugmakers try desperately to change the subject and distract from the issue."
When you have a fee-for-service medical payment system with an insurance buffer between providers, hospitals, pharmaceutical companies and their patients, it's been pretty easy to hide costs.  But it is not sustainable.  In the end, and especially now with Obamacare, we all pay, whether through higher insurance premiums, or higher taxes.

Indeed, whenever the high price of pharmaceuticals is in the news, drugmakers try desperately to change the subject and distract from the issue.

We wanted to bring some reality-check transparency to the situation.  Even if you are blessed not to have the illnesses listed in the above chart, these exorbitant costs affect us all in higher insurance premiums and potentially higher taxes to pay for Obamacare.  We all have to sit up, take notice and hold the drugmakers accountable.

Now more than ever, the industry is under increasing fire for the prices of specialty pharmaceuticals -- some priced at more than $100,000 for a single course of treatment.

Here are some simple facts to consider:

FACT: Astronomical prices for specialty drugs put upward pressure on premiums for all consumers.
At its core, the cost of health insurance is a reflection of the cost of health care. The skyrocketing prices that drugmakers are charging has a ripple effect throughout the system, raising premiums and increasing health care cost for individuals, families, and employers.

FACT: Consumers have out-of-pocket limits that mean health plans and state and federal governments rather than patients are paying the vast
majority of the cost of these exorbitantly-priced drugs. Pharmaceutical companies know that consumers’ out-of-pocket costs are capped
under the Affordable Care Act, allowing them to ask for what amounts to a blank check from insurers and government programs. Not surprisingly, drugmakers are making the law work for them.

FACT: Astronomical prices for specialty drugs will decimate Medicare Part D budgets and force higher premiums for seniors. 
"...some priced at more than $100,000 for a single course of treatment."
An analysis in Health Affairs last week found that the price of the important hepatitis C drug Sovaldi could increase the cost of Medicare Part D and premiums for seniors by 8%. From this one drug alone, seniors on Part D could see an 8% premium hike. 

FACT: Astronomical prices for specialty drugs will devastate state Medicaid budgets and displace important priorities like education and infrastructure.
One recent analysis highlighted on Vox illustrated that, because Sovaldi is so expensive, California could potentially spend more administering the drug for people on Medicaid than it does for K-12 and secondary education combined. Yes, you read that correctly.

FACT: Health plans offer consumers a range of coverage options, including policies with lower cost-sharing.  To distract from their unjustifiable pricing, drugmakers have latched onto distorted coverage comparisons that ignore the range of cost-sharing options consumers can choose from. Hey, anything beats talking about the actual price.

BONUS FACT: Drugmakers have no straight-face explanation to justify the increasingly astronomical prices they have been charging for their medications.
That’s why they want to talk about anything – ANYTHING – other than the prices they are charging.

The most important FACT is that we all want patients to have access to the best treatments. That’s why we cannot afford to allow pharmaceutical companies to have us simply look the other way any longer when it comes to pricing. These unsustain-able drug prices threaten our entire health care system – public and private – access for patients, as well as the very innovation that pharmaceutical companies relish. We cannot have sustainable innovation without sustainable prices to support it, and that’s why health plans and a diverse set of stakeholders have called on drugmakers to come to the table to find a private sector solution to this challenge before the government feels like it needs to.
Source: Buck, Brendan. 6/12/2014 Wow, this drug is really expens — Look! A squirrel!! | AHIP Coverage
http://www.ahipcoverage.com/2014/06/10/wow-this-drug-is-really-expens-look-a-squirrel/ 2/3

Chart: Bloomberg News-DRX Drug Compare/Washington Post/The Fiscal Times

Comments are closed.

    RSS Feed

    Picture
    Rylan Klaseen

    Rylan Klaseen & Associates

    Serving Southern California:
    Tailored Benefits Delivery
    316 W 2nd Street
    Suite 500

    Los Angeles
    CA 90012
    Cell: (909)243-4886

    Archives

    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013

    Categories

    All
    About Rylan Klaseen & Associates
    Affordable Care Act
    Consumer Driven Health Care
    Employee Benefits
    Healthcare Costs
    Healthcare Quality
    Recruiting
    Retention
    Voluntary
    Workplace Wellness

    Stay informed! Subscribe to our mailing list

    * required

    RSS Feed

    Insurance Agents Rancho Cucamonga
    Tweets by @RylanKlaseen
Rylan Klaseen & Associates          Tailored Benefits Delivery          Serving Southern California
316 W 2nd Street, Suite 500, Los Angeles, CA 90012 Cell 909-243-4886